The Comeback Begins? Positive Signs Seen For Humira Biosimilars In US
Sandoz Gets Adalimumab Bump And Teva/Alvotech Strike Deal, As Market Share Doubles In Q1
After getting off to a slow start last year, US biosimilar rivals to Humira are beginning to gain more traction. Sandoz is increasing its share on a weekly basis, Alvotech and Teva have struck a deal for their newly-approved interchangeable 100mg/ml biosimilar, and the latest market data shows biosimilars capturing twice as much of the market in Q1 as in Q4 2023.
